{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:21:34Z","timestamp":1791897694081,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002544"],"award-info":[{"award-number":["UL1TR002544"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["ML42663"],"award-info":[{"award-number":["ML42663"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL111024"],"award-info":[{"award-number":["R01 HL111024"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL135142"],"award-info":[{"award-number":["R01 HL135142"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL1130974"],"award-info":[{"award-number":["R01 HL1130974"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Interstitial lung abnormalities (ILA) are CT findings suggestive of interstitial lung disease in individuals without a prior diagnosis or suspicion of ILD. Previous studies have demonstrated that ILA are associated with clinically significant outcomes including mortality.\u00a0The aim of this study was to determine the prevalence of ILA in a large CT lung cancer screening program and the association with clinically significant outcomes including mortality, hospitalizations, cancer and ILD diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective study of individuals enrolled in a CT lung cancer screening program from 2012 to 2014. Baseline and longitudinal CT scans were scored for ILA per Fleischner Society guidelines. The primary analyses examined the association between baseline ILA and mortality, all-cause hospitalization, and incidence of lung cancer. Kaplan\u2013Meier plots were generated to visualize the associations between ILA and lung cancer and all-cause mortality. Cox regression proportional hazards models were used to test for this association in both univariate and multivariable models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>1699 subjects met inclusion criteria. 41 (2.4%) had ILA and 101 (5.9%) had indeterminate ILA on baseline CTs. ILD was diagnosed in 10 (24.4%) of 41 with ILA on baseline CT with a mean time from baseline CT to diagnosis of 4.47\u2009\u00b1\u20092.72\u00a0years. On multivariable modeling, the presence of ILA remained a significant predictor of death, HR 3.87 (2.07, 7.21; p\u2009&lt;\u20090.001) when adjusted for age, sex, BMI, pack years and active smoking, but not of lung cancer and all-cause hospital admission. Approximately 50% with baseline ILA had progression on the longitudinal scan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ILA identified on baseline lung cancer screening exams are associated with all-cause mortality. In addition, a significant proportion of patients with ILA are subsequently diagnosed with ILD and have CT progression on longitudinal scans.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration number<\/jats:italic>\n                      : ClinicalTrials.gov; No.: NCT04503044.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-023-02359-9","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:48:42Z","timestamp":1676335722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Interstitial lung abnormalities in a large clinical lung cancer screening cohort: association with mortality and ILD diagnosis"],"prefix":"10.1186","volume":"24","clinical-trial-number":[{"clinical-trial-number":"nct04503044","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Avignat S.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn M.","family":"Regis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary M.","family":"Hunninghake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori Lyn","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Gawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea B.","family":"McKee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly M.","family":"Rieger-Christ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Pinto-Plata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy N.","family":"Liesching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Hashim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady J.","family":"McKee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Gazourian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"issue":"10","key":"2359_CR1","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1056\/NEJMoa1007285","volume":"364","author":"GR Washko","year":"2011","unstructured":"Washko GR, Hunninghake GM, Fernandez IE, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med. 2011;364(10):897\u2013906.","journal-title":"N Engl J Med"},{"issue":"5","key":"2359_CR2","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1136\/thoraxjnl-2018-212446","volume":"74","author":"GM Hunninghake","year":"2019","unstructured":"Hunninghake GM. Interstitial lung abnormalities: erecting fences in the path towards advanced pulmonary fibrosis. Thorax. 2019;74(5):506\u201311.","journal-title":"Thorax"},{"issue":"7","key":"2359_CR3","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S2213-2600(20)30168-5","volume":"8","author":"H Hatabu","year":"2020","unstructured":"Hatabu H, Hunninghake GM, Richeldi L, et al. Interstitial lung abnormalities detected incidentally on CT: a position paper from the Fleischner Society. Lancet Respir Med. 2020;8(7):726\u201337.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"2359_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1164\/rccm.201809-1652OC","volume":"200","author":"RK Putman","year":"2019","unstructured":"Putman RK, Gudmundsson G, Axelsson GT, et al. Imaging patterns are associated with interstitial lung abnormality progression and mortality. Am J Respir Crit Care Med. 2019;200(2):175\u201383.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"2359_CR5","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jama.2016.0518","volume":"315","author":"RK Putman","year":"2016","unstructured":"Putman RK, Hatabu H, Araki T, et al. Association between interstitial lung abnormalities and all-cause mortality. JAMA. 2016;315(7):672\u201381.","journal-title":"JAMA"},{"issue":"12","key":"2359_CR6","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1164\/rccm.201512-2523OC","volume":"194","author":"T Araki","year":"2016","unstructured":"Araki T, Putman RK, Hatabu H, et al. Development and progression of interstitial lung abnormalities in the Framingham heart study. Am J Respir Crit Care Med. 2016;194(12):1514\u201322.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"2359_CR7","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.chest.2019.06.041","volume":"156","author":"S-A Whittaker Brown","year":"2019","unstructured":"Whittaker Brown S-A, Padilla M, Mhango G, et al. Interstitial lung abnormalities and lung cancer risk in the national lung screening trial. Chest. 2019;156(6):1195\u2013203.","journal-title":"Chest"},{"key":"2359_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30168-5","author":"GT Axelsson","year":"2020","unstructured":"Axelsson GT, Putman RK, Aspelund T, et al. The associations of interstitial lung abnormalities with cancer diagnoses and mortality. Eur Respir J. 2020. https:\/\/doi.org\/10.1016\/S2213-2600(20)30168-5.","journal-title":"Eur Respir J."},{"key":"2359_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.06.035","author":"GM Hunninghake","year":"2021","unstructured":"Hunninghake GM, Goldin JG, Kadoch MA, et al. Detection and early referral of patients with interstitial lung abnormalities: an expert survey initiative. Chest. 2021. https:\/\/doi.org\/10.1016\/j.chest.2021.06.035.","journal-title":"Chest"},{"issue":"22","key":"2359_CR10","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King","year":"2014","unstructured":"King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083\u201392.","journal-title":"N Engl J Med"},{"issue":"22","key":"2359_CR11","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"issue":"7","key":"2359_CR12","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/17476348.2018.1472580","volume":"12","author":"M Molina-Molina","year":"2018","unstructured":"Molina-Molina M, Aburto M, Acosta O, et al. Importance of early diagnosis and treatment in idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2018;12(7):537\u20139.","journal-title":"Expert Rev Respir Med"},{"issue":"18","key":"2359_CR13","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"issue":"1","key":"2359_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12931-019-1022-1","volume":"20","author":"M Kolb","year":"2019","unstructured":"Kolb M, Va\u0161\u00e1kov\u00e1 M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20(1):57.","journal-title":"Respir Res"},{"key":"2359_CR15","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0100-2018","author":"V Cottin","year":"2019","unstructured":"Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. 2019. https:\/\/doi.org\/10.1183\/16000617.0100-2018.","journal-title":"Eur Respir Rev."},{"key":"2359_CR16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00085-2020","author":"KK Brown","year":"2020","unstructured":"Brown KK, Martinez FJ, Walsh SLF, et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020. https:\/\/doi.org\/10.1183\/13993003.00085-2020.","journal-title":"Eur Respir J."},{"issue":"4","key":"2359_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431\u201340.","journal-title":"Am J Respir Crit Care Med"},{"key":"2359_CR18","doi-asserted-by":"publisher","first-page":"17074","DOI":"10.1038\/nrdp.2017.74","volume":"3","author":"FJ Martinez","year":"2017","unstructured":"Martinez FJ, Collard HR, Pardo A, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3:17074.","journal-title":"Nat Rev Dis Primers"},{"key":"2359_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2020-000567","author":"LD Snyder","year":"2020","unstructured":"Snyder LD, Mosher C, Holtze CH, et al. Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO registry. BMJ Open Respir Res. 2020. https:\/\/doi.org\/10.1136\/bmjresp-2020-000567.","journal-title":"BMJ Open Respir Res"},{"issue":"2","key":"2359_CR20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.6004\/jnccn.2012.0022","volume":"10","author":"DE Wood","year":"2012","unstructured":"Wood DE, Eapen GA, Ettinger DS, et al. Lung cancer screening. J Natl Compr Canc Netw. 2012;10(2):240\u201365.","journal-title":"J Natl Compr Canc Netw"},{"key":"2359_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106245","volume":"176","author":"L Gazourian","year":"2021","unstructured":"Gazourian L, Thedinger WB, Regis SM, et al. Qualitative emphysema and risk of COPD hospitalization in a multicenter CT lung cancer screening cohort study. Respir Med. 2021;176: 106245.","journal-title":"Respir Med"},{"key":"2359_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106540","volume":"186","author":"L Gazourian","year":"2021","unstructured":"Gazourian L, Regis SM, Pagura EJ, et al. Qualitative coronary artery calcification scores and risk of all cause, COPD and pneumonia hospital admission in a large CT lung cancer screening cohort. Respir Med. 2021;186: 106540.","journal-title":"Respir Med"},{"issue":"2","key":"2359_CR23","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1016\/j.jacr.2015.12.009","volume":"13","author":"BJ McKee","year":"2016","unstructured":"McKee BJ, Regis SM, McKee AB, Flacke S, Wald C. Performance of ACR Lung-RADS in a clinical CT lung screening program. J Am Coll Radiol. 2016;13(2):R25\u20139.","journal-title":"J Am Coll Radiol"},{"issue":"5","key":"2359_CR24","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44\u201368.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2359_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S2213-2600(17)30433-2","volume":"6","author":"DA Lynch","year":"2018","unstructured":"Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018;6(2):138\u201353.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2359_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12931-019-1076-0","volume":"20","author":"N Hoyer","year":"2019","unstructured":"Hoyer N, Prior TS, Bendstrup E, Wilcke T, Shaker SB. Risk factors for diagnostic delay in idiopathic pulmonary fibrosis. Respir Res. 2019;20(1):103.","journal-title":"Respir Res"},{"issue":"2","key":"2359_CR27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1148\/radiol.13120816","volume":"268","author":"GY Jin","year":"2013","unstructured":"Jin GY, Lynch D, Chawla A, et al. Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate. Radiology. 2013;268(2):563\u201371.","journal-title":"Radiology"},{"key":"2359_CR28","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1378\/chest.12-2403","volume":"144","author":"CJ Ryerson","year":"2013","unstructured":"Ryerson CJ, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013;144:234\u201340.","journal-title":"Chest"},{"key":"2359_CR29","first-page":"221172","volume":"11","author":"JE Lee","year":"2022","unstructured":"Lee JE, Chae KJ, Suh YJ, et al. Prevalence and long-term outcomes of CT interstitial lung abnormalities in a health screening cohort. Radiology. 2022;11:221172.","journal-title":"Radiology"},{"issue":"5","key":"2359_CR30","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1148\/rg.2017170056","volume":"37","author":"MG Lubner","year":"2017","unstructured":"Lubner MG, Smith AD, Sandrasegaran K, Sahani DV, Pickhardt PJ. CT texture analysis: definitions, applications, biologic correlates, and challenges. Radiographics. 2017;37(5):1483\u2013503.","journal-title":"Radiographics"},{"issue":"8","key":"2359_CR31","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.acra.2016.08.023","volume":"24","author":"SY Ash","year":"2017","unstructured":"Ash SY, Harmouche R, Ross JC, Diaz AA, Hunninghake GM, Putman RK, Onieva J, Martinez FJ, Choi AM, Lynch DA, Hatabu H, Rosas IO, Estepar RSJ, Washko GR. The objective identification and quantification of interstitial lung abnormalities in smokers. Acad Radiol. 2017;24(8):941\u20136.","journal-title":"Acad Radiol"},{"issue":"1","key":"2359_CR32","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41598-019-56989-5","volume":"10","author":"D Bermejo-Pel\u00e1ez","year":"2020","unstructured":"Bermejo-Pel\u00e1ez D, Ash SY, Washko GR, San Jos\u00e9 Est\u00e9par R, Ledesma-Carbayo MJ. Classification of interstitial lung abnormality patterns with an ensemble of deep convolutional neural networks. Sci Rep. 2020;10(1):338.","journal-title":"Sci Rep"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02359-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02359-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02359-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:50:17Z","timestamp":1676335817000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02359-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2359"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02359-9","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"assertion":[{"value":"20 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Lahey Clinic, Inc, Institutional Review Board, Protocol #20203157. The need for individual consent was waived by the IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.S.P., E.M., J.H., B.J.M, and L.G. were supported by a grant from Genentech, Inc. G.M.H reports consulting fees from Boehringer-Ingelheim and Gerson Lehrman Group outside the submitted work. A.B.M. reports consulting fees from Astra Zeneca outside the submitted work. B.J.M. reports consulting fees from Astra Zeneca and royalties from UpToDate\u00ae outside the submitted work. L.L.P, M.G., K.R\u2013C., T.N.L, V.P-P., C.W. report none.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}